Article Details
Retrieved on: 2019-02-11 03:14:52
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>... is developing drugs focused on immunology, raised over $300 million in venture capital funding from investors like ARCH and <b>Polaris Partners</b>.</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here